AU6240494A - Ribosome inactivating protein compositions having reduced antigenicity - Google Patents

Ribosome inactivating protein compositions having reduced antigenicity

Info

Publication number
AU6240494A
AU6240494A AU62404/94A AU6240494A AU6240494A AU 6240494 A AU6240494 A AU 6240494A AU 62404/94 A AU62404/94 A AU 62404/94A AU 6240494 A AU6240494 A AU 6240494A AU 6240494 A AU6240494 A AU 6240494A
Authority
AU
Australia
Prior art keywords
protein compositions
inactivating protein
ribosome inactivating
reduced antigenicity
antigenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62404/94A
Inventor
Carl W Gilbert
Terrace W Hallahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Inc filed Critical Enzon Inc
Publication of AU6240494A publication Critical patent/AU6240494A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU62404/94A 1993-02-16 1994-02-14 Ribosome inactivating protein compositions having reduced antigenicity Abandoned AU6240494A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1772693A 1993-02-16 1993-02-16
US017726 1993-02-16
PCT/US1994/001618 WO1994019007A1 (en) 1993-02-16 1994-02-14 Ribosome inactivating protein compositions having reduced antigenicity

Publications (1)

Publication Number Publication Date
AU6240494A true AU6240494A (en) 1994-09-14

Family

ID=21784202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62404/94A Abandoned AU6240494A (en) 1993-02-16 1994-02-14 Ribosome inactivating protein compositions having reduced antigenicity

Country Status (2)

Country Link
AU (1) AU6240494A (en)
WO (1) WO1994019007A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948347A4 (en) * 1997-07-16 2000-08-30 Sophie Chen Antiviral and antitumor agents
CN1322243A (en) 1998-08-06 2001-11-14 杜克大学 Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2245114T3 (en) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. CONJUGATES OF PEG-OXIDASA DE URATO AND ITS USE.
PT3321359T (en) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
CN101194016B (en) 2005-04-11 2012-09-05 萨文特医药公司 A variant form of urate oxidase and use thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
SG10201408480RA (en) 2009-06-25 2015-02-27 Crealta Pharmaceuticals Llc Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy

Also Published As

Publication number Publication date
WO1994019007A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
AU7043394A (en) Association peptides
AU1120495A (en) Bactericidal composition
AU7407594A (en) Therapeutic compositions comprising a polypeptide
AU5794094A (en) Tricritical point composition
AU4514193A (en) Bone formation-inducing protein
AU6831594A (en) Novel tracheal antimicrobial peptides
EP0607012A3 (en) Compressor
AU1751892A (en) Novel peptide compositions and uses therefor
AU6939594A (en) Stapler
AU7437094A (en) Disinfectant-detergent composition
AU6240494A (en) Ribosome inactivating protein compositions having reduced antigenicity
AU6751394A (en) Mixing-cutting paddle
AU1280095A (en) Bactericidal composition
AU7084994A (en) Herbicidal compositions
AU5773994A (en) Cable-making compositions
AU5789594A (en) Odorant compositions
AU6377594A (en) Disinfectant compositions
AU7163694A (en) Curable compositions
AU6945996A (en) Novel amino resin compositions
PL302321A1 (en) Antimicrobial proteins
AU1200495A (en) Ranitidine compositions
AU672124B2 (en) Composition
AU7661994A (en) Photopolymerisable composition
AU8228591A (en) Antimicrobial peptides
AU6021794A (en) Ophthalmic compositions comprising benzyllauryldimethylammonium chloride